AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
Log in

NYSEAMERICAN:MTNBMatinas BioPharma Stock Price, Forecast & News

$0.87
+0.02 (+2.34 %)
(As of 06/4/2020 10:07 AM ET)
Add
Compare
Today's Range
$0.87
Now: $0.87
$0.90
50-Day Range
$0.59
MA: $0.67
$0.73
52-Week Range
$0.49
Now: $0.87
$2.49
Volume249,818 shs
Average Volume2.36 million shs
Market Capitalization$172.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.
Read More
Matinas BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:MTNB
CUSIPN/A
CIKN/A
Phone+1-908-4431860

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees21
Market Cap$172.74 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Matinas BioPharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Matinas BioPharma.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Matinas BioPharma.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.03) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.03). View Matinas BioPharma's earnings history.

What price target have analysts set for MTNB?

5 Wall Street analysts have issued twelve-month target prices for Matinas BioPharma's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Matinas BioPharma's share price to reach $3.30 in the next year. This suggests a possible upside of 277.1% from the stock's current price. View analysts' price targets for Matinas BioPharma.

What are Wall Street analysts saying about Matinas BioPharma stock?

Here are some recent quotes from research analysts about Matinas BioPharma stock:
  • 1. According to Zacks Investment Research, "Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. " (3/25/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $4/share is based on an equally weighted composite of: (a) $2.47/share, as a 35x multiple of taxed and diluted 2033 EPS of $0.67 discounted back to 2019 at 18%; and (b) an NPV discounted cash flow between 2019-2033 of $4.81/share, with a discount rate of 12% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/14/2019)

Has Matinas BioPharma been receiving favorable news coverage?

Headlines about MTNB stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Matinas BioPharma earned a news impact score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutMatinas BioPharma.

Who are some of Matinas BioPharma's key competitors?

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include Outlook Therapeutics (OTLK), Amplify Energy (AMPY), Amplify Energy (AMPY), Unum Therapeutics (UMRX), KushCo (KSHB), SCYNEXIS (SCYX), Acasti Pharma (ACST), ADMA Biologics (ADMA), Nokia Oyj (NOK) and Titan Pharmaceuticals (TTNP).

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the following people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 46, Pay $644.79k)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 50, Pay $249.05k)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 53, Pay $380.62k)
  • Dr. James J. Ferguson, Chief Medical Officer (Age 67, Pay $461.46k)
  • Dr. Raphael J. Mannino, Chief Scientific Officer (Age 73)

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Vivo Capital LLC (5.71%), Victory Capital Management Inc. (1.98%), Victory Capital Management Inc. (1.98%), BlackRock Inc. (1.11%), Geode Capital Management LLC (0.55%) and Morgan Stanley (0.36%). Company insiders that own Matinas BioPharma stock include Adam K Stern, Herbert J Conrad, Jerome D Jabbour, Keith A Kucinski and Patrick G Lepore. View institutional ownership trends for Matinas BioPharma.

Which major investors are selling Matinas BioPharma stock?

MTNB stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, and WINTON GROUP Ltd. View insider buying and selling activity for Matinas BioPharma.

Which major investors are buying Matinas BioPharma stock?

MTNB stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Victory Capital Management Inc., Victory Capital Management Inc., Morgan Stanley, Two Sigma Investments LP, Water Island Capital LLC, DCF Advisers LLC, and Jane Street Group LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, Herbert J Conrad, Jerome D Jabbour, Keith A Kucinski, and Patrick G Lepore. View insider buying and selling activity for Matinas BioPharma.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.88.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $172.80 million. Matinas BioPharma employs 21 workers across the globe.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is www.matinasbiopharma.com.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.